Hims & Hers Health Form 144: Soleil Boughton plans $123K stock sale
Rhea-AI Filing Summary
Hims & Hers Health, Inc. (HIMS) – Form 144 filing
Insider Soleil Boughton has filed a Form 144 indicating an intent to sell 2,572 Class A shares through Fidelity Brokerage Services on or about 14 July 2025. The shares have an aggregate market value of $122,993.04 and account for roughly 0.001% of the company’s 215.45 million shares outstanding, suggesting a limited impact on the public float.
The shares were acquired via restricted-stock vesting on 15 June 2025 and are being disposed of as compensation-related stock. The filer has also disclosed seven prior open-market sales in the past three months totaling 23,535 shares for ~$1.15 million in gross proceeds.
Because Form 144 is a notice of proposed sale, the transaction may or may not be executed, and it does not automatically imply negative operational information. Nonetheless, the continued pattern of insider selling can influence investor perception.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small insider sale (0.001% float); routine but adds to recent $1.15 M selling trend.
The proposed disposal of 2,572 shares worth roughly $123 K is immaterial relative to HIMS’s >215 M shares outstanding and appears linked to stock-based compensation. However, the filing reveals that the same insider liquidated 23,535 shares over the previous quarter, generating about $1.15 M in proceeds. While this pattern may raise questions about insider sentiment, the scale remains minor and should not significantly affect liquidity or share price. Investors should view the notice as neutral to slightly negative, monitoring for larger or broader insider selling that could signal confidence shifts.